The International Journal of Neuropsychopharmacology

Table of Contents - 2004 - Volume 7, Issue 02  


Focus

Focus on Polypharmacy in schizophrenia: does anyone truly benefit? 1

Donald C. Goff a1a2c1 and Oliver Freudenreich a1a2
a1 Schizophrenia Program, Massachusetts General Hospital, Boston, MA, USA
a2 Harvard Medical School, Boston, MA, USA

Article author query
goff d   [PubMed][Google Scholar] 
freudenreich o   [PubMed][Google Scholar] 

Dr Suzuki and colleagues (Suzuki et al., 2004) are to be commended for their contribution of a novel, systematic study of polypharmacy in schizophrenia – a surprisingly under-studied topic given its high prevalence worldwide. We find their results quite informative and agree with their thoughtful and very balanced discussion of their results.


Correspondence:
c1 Dr D. C. Goff, Freedom Trail Clinic, 25 Staniford St., Boston, MA 02114, USA. Tel.: (617) 912-7899 Fax: (617) 723-3919 E-mail: goff@psych.mgh.harvard.edu

Footnotes

1 See Suzuki et al. p. 133–142. Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia.


Related Content
--